Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
GlobalData on MSN2d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
pharmaphorum2d
FDA sets June date for Gilead's twice-yearly HIV PrEP
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
Gilead price target raised to $120 from $105 at Bernstein
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Managed Healthcare Executive2d
FDA Accepts NDA for Gilead's New HIV Prevention Shot
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
Pharmabiz1d
US FDA accepts Gilead’s NDA for twice-yearly lenacapavir for HIV prevention under priority review
Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...
Bay Area Reporter2d
Twice-yearly PrEP could be available this summer
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Healio3d
FDA sets date for decision on twice-yearly shots to prevent HIV
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
'Health equity is a business imperative:' Companies work for better Black health outcomes
At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...
Deutsche upgrades Gilead to Buy on ability to offset patent cliffs
Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise ...